Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Consensus PT from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.2333.

A number of equities analysts recently weighed in on IRWD shares. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd.

Insider Activity

In related news, Director Julie Mchugh sold 21,571 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ronald Silver sold 127,890 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. This represents a 28.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 9.30% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC grew its holdings in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares in the last quarter. LSV Asset Management bought a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors purchased a new stake in Ironwood Pharmaceuticals during the second quarter valued at $32,000. Jump Financial LLC purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at $34,000. Finally, DGS Capital Management LLC purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at $35,000.

Ironwood Pharmaceuticals Trading Down 2.6%

Shares of IRWD opened at $4.13 on Monday. The business’s 50 day moving average is $4.14 and its 200 day moving average is $3.90. The company has a market capitalization of $682.44 million, a PE ratio of 5.36 and a beta of 0.20. Ironwood Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. Equities research analysts predict that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.